TSH受体抗体及临床意义

何建华; 曾钦文

TSH受体抗体及临床意义

何建华 , 曾钦文

文章导航 > 国际放射医学核医学杂志 > 2001, 25 > 3: (111-114)

引用本文:

Citation:

TSH受体抗体及临床意义

400026 重庆, 重庆市第二人民医院核医学科

作者简介: 何建华(1963-),男,重庆市人,重庆市第二人民医院核医学科主任,主要从事临床核医学诊断和治疗工作。;曾钦文(1996-),男,重庆市人,重庆市第二人民医院核医学科主治医师,主要从事临床核素治疗工作。;

中图分类号: R446.62

Thyrotropin receptor antibodies and its clinical application

Department of Nuclear Medicine, Second People's Hospital of Chongqing City, Chongqing 400026, China
CLC number: R446.62

摘要: 促甲状腺素受体抗体(TRAb)不是均一性抗体,它至少包括四种抗体,这些抗体的测定在自身免疫性甲状腺疾病GD及其甲状腺以外组织表现以及其他甲状腺疾患的诊断、评估疗效、确定停药时机、预测复发及监测高危人群等方面均具有重要临床意义。
- 促甲状腺受体抗体 /
- 自身免疫性甲状腺疾病
Abstract: Thyrotropin receptor antibodies (T RAb) are not homogeneous, which are composed by four antibodies at least. TRAb plays very important roles in autoimmune thyroid diseases and off-thyroid symptoms associated, and other thyroiditis in clinical diagnosis, assessment of curative effects, determination of the time to stop medicine,prognostication of recurrence and inspection of high risk population.
- thyrotropin receptor antibodies /
- autoimmune thyroid diseases
本作品遵循Signature-Non-Commercial Use 4.0 International (CC BY-NC 4.0)协议

[1]	Watanabe Y,Tahara K,Hirai A,et al.Subtypes of ani-TSH receptor antibodies classified by various as-says using CHO cells expressing wild-type or chimeric human TSH receptor[J].Thyroid,1997,7(1):13-19.
[2]	Akamizu T,M oriyama K,Miura M,et al.Characteri-zation of combinant monoclonal antithyrotropin recep-tor antibodies (TSHRAbs) derived from lymphocytes of patients with Graves' disease:epitope and binding study of two stimulatory TSHRAbs[J].Endocrinolo-gy,1999,140(4):1594-1601.
[3]	AkamizuT,Kohn LD,Hiratani H,et al.Hashimoto's thyroiditis with heterogeneous antithy-rotropin receptor antibodies:unique epitopes may con-tribute to the regulation of thyroid function by the an-tibodies[J].J Clin Endocrinol Metab,2000,85(6):2116-2121.
[4]	Meller J,Jauho A,Hufner M,et al.Disseminated thyroid autonomy or Graves' disease:revaluation by a second generation TSH receptor antibody assay[J].Thyroid,2000,10(12):1073-1079.
[5]	Costagliola S,Morgenthaler NG,Hoermann R,et al.Second generation assay for thyrotropin receptor anti-bodies has superior diagnostic sensitivity for Graves' disease[J].J Clin Endocrinol Metab,1999,84(1):90-97.
[6]	Khoo DH,Eng PH,Ho SC,et al.Graves' ophthal-mopathy in the absence of elevated free thyroxine andtriiodothyronine levels:prevalence,natural history,and thyrotropin receptor antibody levels[J].Thyroid,2000,20(22):1093-1100.
[7]	Morgenthaler NG,Pampel I,Aust G.Application of a bioassay with CHO cells for the routine detection of stimulating and blocking autoantibodies to the TSH-receptor[J].Horm Metab Res,1998,30(3):162-168.
[8]	Giordabo C,Stassi G,De Mria R,et al.Potential in-volve,ent of Fas and its ligand in the pathogenesis of Hashimoto's thyroiditis[J].Scienee,1997,275:960-963.
[9]	Noh JY,Hamada N,Inoue Y,et al.Thyroid-stimu-lating antibody is related to Graves' ophthalmopathy,but thyrotropin-binding inhibitor immunoglobulin is related to hyperthyroidism in patients with Graves' disease[J].Thyroid,2000,10(9):809-813.
[10]	Khoo DH,Ho SC,Seah LL,et al.The combination of absent thyroid peroxidase antibodies and high thyroid-stimulating immunoglobulin levels in Graves' disease identifies a group at markedly increased risk of oph-thalmopathy[J].Thyroid,1999,9(12):1175-1180.
[11]	Gerding MN,van der Meer JW,Broenink M,et al.Association of thyrotrophin receptor antibodies with the clinical features of Graves' ophthalmopathy[J].Clin Endocrinol,2000,52(3):267-271.
[12]	Iitaka M,Momotani N,Hisaoka T,et al.TSH recep-tor antibody-associated thyroid dysfunction following subacute thyroiditis[J].Clin Endocrinol,1998,48(4):445-453.
[13]	Takasu N,Yamashiro K,Komiya I,et al.Remission of Graves' hyperthyroidism predicted by smooth de-creases of thyroid-stimulating antibody and thy-rotropin-binding inhibitor immunoglobulin during an-tithyroid drug treatment[J].Thyroid,2000,10:891-896.
[14]	Momotani N,Yamashita R,Makino F,et al.Thyroid function in wholly breast-feeding infants whose moth-ers take high doses of propylthiouracil[J].Clin En-docrinol,2000.53(2).177-181.
[15]	Jones BM,Kwok CC,Kung AW,et al.Effect of ra-dioactive iodine therapy on cytokine production in Graves' disease:transient increases in interleukin-4(IL-4),IL-6,IL-10,and tumor necrosis factor-alpha,with longn term increses in interferon-gamma produc-tion[J].J Clin Endocrinol Metab,1999,84(11):4106-4110.
[16]	Nygaard B,Knudsen JH,Hegedus L,et al.Thy-rotropin receptor antibodies and Graves' disease,a side-effect of 131 I treatment in patients with nontoxicgoiter[J].J Clin Endocrinol Metab,1997,82 (9):2926-2930.

[1]	张怡 , 袁卫红 . 硒与自身免疫性甲状腺疾病. 国际放射医学核医学杂志, 2012, 36(6): 376-379. doi: 10.3760/cma.j.issn.1673-4114.2012.06.013
[2]	张建媛 , 缪蔚冰 . 电化学发光法与放射性受体分析法检测促甲状腺激素受体抗体的对比研究. 国际放射医学核医学杂志, 2012, 36(1): 20-23. doi: 10.3760/cma.j.issn.1673-4114.2012.01.005
[3]	程维维 , 王辉 . 促甲状腺激素受体与甲状腺癌关系的研究进展. 国际放射医学核医学杂志, 2012, 36(2): 69-71. doi: 10.3760/cma.j.issn.1673-4114.2012.02.002
[4]	黄丽娟 , 陈宁 , 叶静 , 沈炳玲 , 朱云娟 , 孟涛 , 张志洋 , 朱学良 . 反义肽核酸对促甲状腺激素受体mRNA表达的影响. 国际放射医学核医学杂志, 2012, 36(5): 310-312, 319. doi: 10.3760/cma.j.issn.1673-4114.2012.05.011
[5]	关如东 , 刘强 , 李锐 . CT诊断自身免疫性胰腺炎32例分析. 国际放射医学核医学杂志, 2007, 31(6): 387-387.
[6]	胡晓琳 , 张海燕 . Graves'病患者促甲状腺素受体抗体和甲状腺刺激免疫球蛋白水平的变化及临床意义. 国际放射医学核医学杂志, 2006, 30(6): 350-352.
[7]	郭永铁 . 促甲状腺激素与亚临床性甲状腺功能异常. 国际放射医学核医学杂志, 2008, 32(6): 351-353.
[8]	管樑 , 陈刚 . 4项甲状腺自身抗体的变化特征及联合半定量评分在格雷夫斯甲亢¹³¹I治疗后疗效的相关性评估中的临床应用价值. 国际放射医学核医学杂志, 2023, 47(12): 746-751. doi: 10.3760/cma.j.cn121381-202209019-00376
[9]	李铨生 , 林祥通 , 邱传禄 , 张永令 . 游离甲状腺激素放射免疫法测定浓度在研究甲状腺疾病中的意义. 国际放射医学核医学杂志, 1978, 2(4): 51-53.
[10]	刘丽波 , 罗云霄 , 王剑峰 , 陈大伟 , 程光惠 , 金玉珂 . 《放射性甲状腺疾病诊断标准》解读. 国际放射医学核医学杂志, 2012, 36(4): 204-206. doi: 10.3760/cma.j.issn.1673-4114.2012.04.002
[11]	侯祖强 , 吴觉民 . 高脂血干扰促甲状腺激素的测定. 国际放射医学核医学杂志, 1987, 11(4): 253-254.